CureVac NV
CVAC4.660USD
0.0000.00%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
1.05BCap. mercado
9.59P/E TTM
Más Datos de CureVac NV Compañía
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Información de CureVac NV
Símbolo de cotizaciónCVAC
Nombre de la empresaCureVac NV
Fecha de salida a bolsaAug 14, 2020
Director ejecutivoZehnder (Alexander)
Número de empleados825
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 14
DirecciónFriedrich-Miescher-Str. 15
CiudadTUEBINGEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísGermany
Código postal72076
Teléfono49707198830
Sitio Webhttps://www.curevac.com/
Símbolo de cotizaciónCVAC
Fecha de salida a bolsaAug 14, 2020
Director ejecutivoZehnder (Alexander)
Ejecutivos de CureVac NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+23737.00%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+18140.00%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+15563.00%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
-29307.00%
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Alexander Zehnder, M.D.
Dr. Alexander Zehnder, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Myriam Mendila, M.D.
Dr. Myriam Mendila, M.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Mr. Thaminda Ramanayake
Mr. Thaminda Ramanayake
Chief Business Officer, Member of the Management Board
Chief Business Officer, Member of the Management Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+23737.00%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+18140.00%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+15563.00%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
-29307.00%
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
Switzerland
1.06M
85.06%
Belgium (Country)
186.00K
14.94%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: vie., 6 de feb
Actualizado: vie., 6 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Glazer Capital, LLC
2.02%
Alpine Associates Management Inc.
1.02%
Qube Research & Technologies Ltd
0.76%
Bill & Melinda Gates Foundation
0.70%
AQR Capital Management, LLC
0.44%
Otro
95.06%
Accionistas
Accionistas
Proporción
Glazer Capital, LLC
2.02%
Alpine Associates Management Inc.
1.02%
Qube Research & Technologies Ltd
0.76%
Bill & Melinda Gates Foundation
0.70%
AQR Capital Management, LLC
0.44%
Otro
95.06%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
3.01%
Investment Advisor/Hedge Fund
2.14%
Investment Advisor
1.22%
Research Firm
0.89%
Foundation
0.70%
Pension Fund
0.16%
Bank and Trust
0.11%
Individual Investor
0.09%
Sovereign Wealth Fund
0.05%
Otro
91.62%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
242
23.52M
11.47%
+45.36K
2025Q3
254
23.47M
13.08%
+8.57M
2025Q2
251
14.62M
11.55%
+3.90M
2025Q1
235
10.71M
11.20%
-14.51M
2024Q4
236
10.78M
11.68%
-1.77M
2024Q3
244
12.54M
12.61%
-3.08M
2024Q2
263
15.56M
13.23%
-3.38M
2024Q1
281
18.95M
13.33%
-10.95M
2023Q4
300
23.60M
17.13%
-11.99M
2023Q3
318
35.42M
18.08%
-1.78M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Glazer Capital, LLC
4.55M
2.02%
+3.95M
+664.34%
Sep 30, 2025
Alpine Associates Management Inc.
2.30M
1.02%
+324.25K
+16.45%
Sep 30, 2025
Qube Research & Technologies Ltd
1.71M
0.76%
+530.69K
+44.90%
Sep 30, 2025
Bill & Melinda Gates Foundation
1.57M
0.7%
-28.77K
-1.80%
Sep 30, 2024
AQR Capital Management, LLC
991.69K
0.44%
+947.53K
+2145.72%
Sep 30, 2025
Water Island Capital, LLC
762.14K
0.34%
-194.89K
-20.36%
Sep 30, 2025
Magnetar Capital Partners LP
654.80K
0.29%
+654.80K
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
550.09K
0.24%
-30.29K
-5.22%
Sep 30, 2025
RBC Dominion Securities, Inc.
500.60K
0.22%
+499.64K
+52154.49%
Sep 30, 2025
Bridgewater Associates, LP
466.41K
0.21%
+466.41K
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
AltShares Merger Arbitrage ETF
1.3%
Virtus LifeSci Biotech Clinical Trials ETF
0.65%
NYLI Merger Arbitrage ETF
0.57%
Global X Genomics & Biotechnology ETF
0.56%
ProShares Ultra Nasdaq Biotechnology
0.15%
Invesco Nasdaq Biotechnology ETF
0.11%
SPDR S&P International Small Cap ETF
0.05%
iShares Biotechnology ETF
0.04%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
Ver más
AltShares Merger Arbitrage ETF
Proporción1.3%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.65%
NYLI Merger Arbitrage ETF
Proporción0.57%
Global X Genomics & Biotechnology ETF
Proporción0.56%
ProShares Ultra Nasdaq Biotechnology
Proporción0.15%
Invesco Nasdaq Biotechnology ETF
Proporción0.11%
SPDR S&P International Small Cap ETF
Proporción0.05%
iShares Biotechnology ETF
Proporción0.04%
iShares MSCI Europe Small-Cap ETF
Proporción0.04%
iShares MSCI EAFE Small-Cap ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
